Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in North Carolina: - Atrium Health Stanly/LCI-Albemarle — Albemarle, North Carolina
- Duke Cancer Center Cary — Cary, North Carolina
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Atrium Health Pineville/LCI-Pineville — Charlotte, North Carolina
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, su…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06661720
Sites in North Carolina: - Duke Cancer Center Cary — Cary, North Carolina
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Duke University Medical Center — Durham, North Carolina
- Duke Cancer Center Southpoint — Durham, North Carolina
- FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina
Phase 3 Recruiting Network
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spr…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04510597
Sites in North Carolina: - Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
- Southeastern Medical Oncology Center-Goldsboro — Goldsboro, North Carolina
- Southeastern Medical Oncology Center-Jacksonville — Jacksonville, North Carolina
Phase 3 Recruiting Industry
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carc…
Sponsor: Arcus Biosciences, Inc.
NCT ID: NCT07011719
Sites in North Carolina: - UNC Hospitals — Chapel Hill, North Carolina
Phase 3 Recruiting Academic/Other
The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT07092566
Sites in North Carolina: - Levine Cancer — Charlotte, North Carolina
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Margaret R Pardee Memorial Hospital — Hendersonville, North Carolina
Phase 2 Recruiting Academic/Other
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with re…
Sponsor: NRG Oncology
NCT ID: NCT05327686
Sites in North Carolina: - Duke Cancer Center Cary — Cary, North Carolina
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Atrium Health Pineville/LCI-Pineville — Charlotte, North Carolina
- Atrium Health University City/LCI-University — Charlotte, North Carolina
Phase 2 Recruiting Network
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Dru…
Sponsor: Children's Oncology Group
NCT ID: NCT04322318
Sites in North Carolina: - Mission Hospital — Asheville, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Novant Health Presbyterian Medical Center — Charlotte, North Carolina
- Duke University Medical Center — Durham, North Carolina
- East Carolina University — Greenville, North Carolina
Phase 1, Phase 2 Recruiting Industry
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage.…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06413680
Sites in North Carolina: - University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in co…
Sponsor: Aulos Bioscience, Inc.
NCT ID: NCT05267626
Sites in North Carolina: - Carolina Biooncology Institute — Huntersville, North Carolina
Phase 1, Phase 2 Recruiting Industry
Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experi…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07049926
Sites in North Carolina: - Duke Cancer Institute ( Site 5015) — Durham, North Carolina
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
This is a phase 2 stratified, randomized, multicenter, study investigating the efficacy of a triplet arm treating with nivolumab 480 mg every 4 weeks (Q4W), relatlimab 160 mg Q4W and ipilimumab 1 mg/kg every 8 weeks (Q8W) intravenous (IV) …
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06708949
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic…
Sponsor: GI Innovation, Inc.
NCT ID: NCT04977453
Sites in North Carolina: - Carolina Biooncology Institute — Huntersville, North Carolina
Phase 2 Recruiting Academic/Other
This is a 4-arm, single-center study involving 40 participants. Ten healthy volunteers will be enrolled for system imaging optimization, and thirty (30) patients with previously identified lesions in the breast, liver, or kidney-based on p…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT07225114
Sites in North Carolina: - The University of North Carolina — Chapel Hill, North Carolina
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in North Carolina: - Exelixis Clinical Site #12 — Durham, North Carolina
Phase 1 Recruiting Industry
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and …
Sponsor: Xencor, Inc.
NCT ID: NCT05433142
Sites in North Carolina: - Xencor Investigative Site — Charlotte, North Carolina
- Xencor Investigative Site — Durham, North Carolina
Phase 1 Recruiting Industry
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JAN…
Sponsor: Janux Therapeutics
NCT ID: NCT05783622
Sites in North Carolina: - University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
Phase 1 Recruiting Industry
The study will assess the safety, PK, PD, and preliminary efficacy of ABBVCLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (T…
Sponsor: Calico Life Sciences LLC
NCT ID: NCT04777994
Sites in North Carolina: - Duke Cancer Center /ID# 251975 — Durham, North Carolina
- Carolina BioOncology Institute /ID# 225704 — Huntersville, North Carolina
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in North Carolina: - AdventHealth Infusion Center Asheville — Asheville, North Carolina
- UNC Health Cancer Care Cary — Cary, North Carolina
- Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
- AdventHealth Infusion Center Haywood — Clyde, North Carolina
- Durham VA Medical Center — Durham, North Carolina
Recruiting Network
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going ca…
Sponsor: Children's Oncology Group
NCT ID: NCT02402244
Sites in North Carolina: - Mission Hospital — Asheville, North Carolina
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Novant Health Presbyterian Medical Center — Charlotte, North Carolina
- Duke University Medical Center — Durham, North Carolina
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in North Carolina: - Massive Bio SYNERGY-AI site — Chapel Hill, North Carolina
- Massive Bio SYNERGY-AI site — Winston-Salem, North Carolina
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in North Carolina: - Cape Fear Valley Health System — Fayetteville, North Carolina
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in North Carolina: - UNC- Chapel Hill — Chapel Hill, North Carolina
Recruiting Industry
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
Sponsor: UroGen Pharma Ltd.
NCT ID: NCT05874921
Sites in North Carolina: - The University of North Carolina Chapel Hill — Chapel Hill, North Carolina